ALFA FinderBSE filing, NSE: IOLCP. Summary written from the filing by ALFA Finder's alert engine.
IOL Chemicals and Pharmaceuticals Ltd: key numbers
- Share price
- ₹183.29
- Market cap
- ₹5,380 Cr
- Revenue (annual)
- ₹2,319 Cr
- Net profit (annual)
- ₹137.6 Cr
- P/E (TTM)
- 26.5×Sector 43.0×
- Promoter holding
- 62.28%+0.00% QoQ
- FII holding
- 7.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IOL Chemicals and Pharmaceuticals Ltd
All →IOL Chemicals and Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue INR795 cr (+40% YoY), EBITDA INR115 cr (14.4% margin), PAT INR65 cr (+117%). Management now guides ~25%+ FY27 revenue growth.
- Call
- Guides 25% growth
IOL Chemicals and Pharmaceuticals Earnings Call Transcript: Key Takeaways
IOL Chemicals delivered strong Q2 results with significant profitability improvements, driven by non-Ibuprofen API growth and cost efficiencies, despite rising raw material prices.
- Call
- Guides 25% growth
IOL Chemicals and Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 standalone revenue ₹795 Cr (+40.1% YoY), EBITDA ₹114.9 Cr (14.4% margin), PAT ₹65 Cr (+116.8%). H1 revenue ₹1,551 Cr (+38.6%). Pivoting to high-value APIs with ₹495 Cr capex plan.
IOL Chemicals and Pharmaceuticals Results Update
IOL Chemicals reported record quarterly revenue, EBITDA and profit for Q2 FY27 and half-year results. Standalone growth was strong, with margins expanding year-on-year.
IOL Chemicals and Pharmaceuticals Q2 FY27 Results: Net Profit ₹65.1 Cr, Up 117.0% YoY
IOL Chemicals and Pharmaceuticals Ltd reported revenue from operations of ₹795 Cr (+40.1% YoY) and net profit of ₹65.1 Cr (+117.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹65.1 Cr · +117.0% YoY
IOL Chemicals and Pharmaceuticals Board Meeting Date
IOL Chemicals scheduled its board meeting for 30 Oct 2026 to consider unaudited Q1/H1 results. Trading window remains closed until 2 Nov 2026.
Other annual report announcements
All →Vineet Laboratories Annual Report
Vineet Laboratories filed its FY 2025-26 Annual Report, which marks its turnaround and recapitalisation year. The AGM is scheduled for 30 November 2026.
Indrayani Biotech Annual Report
Indrayani Biotech has filed its 34th Annual Report for FY2025-26, containing the AGM notice for 30 November 2026 by VC/OAVM. The chairman notes a Rights Issue was initiated in October 2026 to raise capital.
ESDS Software Solution Annual Report
ESDS Software Solution submitted its FY2025-26 Annual Report along with the AGM notice. The AGM is on 30 November 2026 via VC/OAVM, with remote e-voting.
The Orissa Minerals Development Company Annual Report
Orissa Minerals Development Company filed its FY 2025-26 Annual Report and 108th AGM notice, with the AGM set for 30 November 2026. The filing is a Regulation 34 intimation with no transaction or financial event.
Viksit Engineering Annual Report
Viksit Engineering filed its 44th Annual Report for FY 2025-26 with BSE. The report includes notice of the AGM on 30 November 2026.
Innovision Annual Report
Innovision Ltd filed its FY2025-26 Annual Report with the notice of its 20th AGM, scheduled for 5 December 2026 via VC/OAVM. The notice covers financial statements, a director re-appointment and a non-executive director regularisation.